March 31st 2021
Sponsored Content by Ipsen
March 30th 2021
Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.
January 26th 2021
December 16th 2020
Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.
October 20th 2020
As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.
September 18th 2020
Questions and answers with Dr. Eunice Wang, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, an unpaid Astellas consultant
July 21st 2020
While great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.